An observational study in Chronic Kidney Disease, Hypertension and T2DM (Type 2 Diabetes Mellitus), sponsored by Centre Mohammed VI de la Recherche et de l'Innovation (CM6RI). Not yet recruiting. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by Centre Mohammed VI de la Recherche et de l'Innovation (CM6RI) · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a non-interventional study being conducted to validate the performance of a machine learning algorithm for prediction of eGFR from digital retinal images in a target population for future intended use as a populated-based screening tool. Secondary objectives will include prediction of blood pressure (> or ≤ 140/90 mmHg) and presence or absence of T2DM as determined by glycated haemoglobin (HbA1c >6.5%) or on the basis of clinical history. Once validated, the methodology will be deployed for health screening to improve access to healthcare.
3,096 studies on the registry are indexed under Renal Insufficiency, Chronic; 701 are open to participants now.
This study's planned enrollment of 500 is above the median of 213 across 834 observational studies indexed under Renal Insufficiency, Chronic.
Browse Renal Insufficiency, Chronic studies →Centre Mohammed VI de la Recherche et de l'Innovation (CM6RI) is the lead sponsor of 2 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
The study population consists of adult patients diagnosed with chronic kidney disease (CKD), hypertension, diabetes mellitus, or without these conditions, attending routine outpatient clinics at Hôpital Universitaire International Cheikh Khalifa Ibn Zaid in Casablanca and Centre Hospitalier Universitaire Hassan II in Fez, Morocco.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participants are eligible to be included in the study only if all of the following criteria apply:
Exclusion Criteria:
Participants are excluded from the study if any of the following criteria apply:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
350 participants (cases) with diabetes and/or hypertension and/or CKD with previously documented eGFR \< 60 ml/min/1.73m2 ≥3 months
Diagnostic Test: Machine Learning-Based Algorithm
150 (controls) with previously documented eGFR ≥ 60 ml/min/1.73m2 ≥ 3 months
Diagnostic Test: Machine Learning-Based Algorithm
A machine learning-based algorithm analyzes retinal images to assess its ability to detect chronic kidney disease
The accuracy of a machine-learning based algorithm to predict high risk CKD from digital retinal images
To quantify the discrimination of the machine-learning algorithm for identifying the binary target condition of persistent eGFR \<60 mL/min/1.73 m², using standard-of-care serum creatinine as the reference standard and the AUROC with a 95% confidence interval as the primary performance measure
Time frame: Baseline
Accuracy of the Machine Learning Algorithm for Detection of Hypertension and T2DM
To quantify the sensitivity, specificity, and discriminative performance of a machine-learning-based algorithm for identifying SBP \>140 mmHg from digital retinal images, using standard-of-care assessment as the reference standard and the AUROC with a 95% confidence interval as the primary performance measure
Time frame: Baseline
No study locations are listed for this record.
Start is estimated for Jan 2027; primary completion for Jun 2027, 5 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Renal Insufficiency, Chronic →
Centre Mohammed VI de la Recherche et de l'Innovation (CM6RI)